These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38866642)

  • 1. Association between N-terminal pro-brain natriuretic peptide and maximal functional capacity in heart failure with preserved ejection fraction: The modifying role of obesity.
    Palau P; Núñez G; de la Espriella R; Miñana G; Domínguez E; Lorenzo M; López L; Flor C; Marín P; Bayés-Genís A; Sanchis J; Núñez J
    Obes Res Clin Pract; 2024; 18(3):226-231. PubMed ID: 38866642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highest Obesity Category Associated With Largest Decrease in N-Terminal Pro-B-Type Natriuretic Peptide in Patients Hospitalized With Heart Failure With Preserved Ejection Fraction.
    Vaishnav J; Chasler JE; Lee YJ; Ndumele CE; Hu JR; Schulman SP; Russell SD; Sharma K
    J Am Heart Assoc; 2020 Aug; 9(15):e015738. PubMed ID: 32750299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction.
    Buckley LF; Canada JM; Del Buono MG; Carbone S; Trankle CR; Billingsley H; Kadariya D; Arena R; Van Tassell BW; Abbate A
    ESC Heart Fail; 2018 Apr; 5(2):372-378. PubMed ID: 29345112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
    Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
    J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial).
    Patel RB; Vaduganathan M; Felker GM; Butler J; Redfield MM; Shah SJ
    Am J Cardiol; 2019 May; 123(10):1660-1666. PubMed ID: 30876658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
    Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
    JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
    Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
    Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.
    Petrie MC; Borlaug BA; Butler J; Davies MJ; Kitzman DW; Shah SJ; Verma S; Jensen TJ; Einfeldt MN; Liisberg K; Perna E; Sharma K; Ezekowitz JA; Fu M; Melenovský V; Ito H; Lelonek M; Kosiborod MN;
    J Am Coll Cardiol; 2024 Jul; 84(1):27-40. PubMed ID: 38819334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction.
    Salah K; Stienen S; Pinto YM; Eurlings LW; Metra M; Bayes-Genis A; Verdiani V; Tijssen JGP; Kok WE
    Heart; 2019 Aug; 105(15):1182-1189. PubMed ID: 30962192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum.
    Faxén UL; Lund LH; Orsini N; Strömberg A; Andersson DC; Linde C; Dahlström U; Savarese G
    Int J Cardiol; 2019 Jul; 287():66-72. PubMed ID: 31005415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NT-proBNP is a weak indicator of cardiac function and haemodynamic response to exercise in chronic heart failure.
    Parovic M; Okwose NC; Bailey K; Velicki L; Fras Z; Seferovic PM; MacGowan GA; Jakovljevic DG
    ESC Heart Fail; 2019 Apr; 6(2):449-454. PubMed ID: 30788904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
    Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
    JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Diastolic Dysfunction with N-terminal Pro-B-type Natriuretic Peptide Level in Heart Failure Patients with Preserved Ejection Fraction.
    Islam MN; Chowdhury MS; Paul GK; Debnath RC; Shakil SS
    Mymensingh Med J; 2019 Apr; 28(2):333-346. PubMed ID: 31086148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
    Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
    Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization.
    Nikolova AP; Hitzeman TC; Baum R; Caldaruse AM; Agvanian S; Xie Y; Geft DR; Chang DH; Moriguchi JD; Hage A; Azarbal B; Czer LS; Kittleson MM; Patel JK; Wu AHB; Kobashigawa JA; Hamilton M; Hong T; Shaw RM
    JAMA Cardiol; 2018 Dec; 3(12):1206-1210. PubMed ID: 30383171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study.
    Carlsen CM; Bay M; Kirk V; Gøtze JP; Køber L; Nielsen OW
    Eur J Heart Fail; 2012 Mar; 14(3):240-7. PubMed ID: 22315457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Midregional pro-atrial natriuretic peptide is a superior biomarker to N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction.
    Cui K; Huang W; Fan J; Lei H
    Medicine (Baltimore); 2018 Sep; 97(36):e12277. PubMed ID: 30200170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
    Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
    Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.